title: Association of TGF-β1 -509C/T polymorphisms with breast cancer risk: evidence from an updated meta-analysis.
abstract: Epidemiological studies have evaluated the association between transforming growth factor-β1 (TGF-β1) -509C/T polymorphisms and breast cancer risk. However, the results remain conflicting rather than conclusive. The aim of this study was to comprehensively clarify the association between TGF-β1 -509C/T polymorphisms and breast cancer risk. All relevant studies were searched in the electronic databases. The potential sources of heterogeneity were detected with the chi-square-based Q test. The strength of associations between TGF-β1 -509C/T polymorphisms and breast cancer risk was measured by odds ratio (OR) and 95 % confidence intervals (CI). Publication bias was tested by Begg's test and Egger's test. A total of 10 studies including 10,913 cases and 14,187 controls were included in the meta-analysis. Overall, there was no evidence of significant association of TGF-β1 -509C/T polymorphisms with breast cancer risk (TT vs. CC [OR = 0.97, 95 % CI = 0.83-1.14]; CT vs. CC [OR = 1.05, 95 % CI = 0.90-1.22]; TT + CT vs. CC [OR = 0.99, 95 % CI = 0.91-1.08]; T allele vs. C allele [OR = 0.99, 95 % CI = 0.93-1.06]). Similar results were also found in the subgroup analyses by ethnicity and source of control. When stratified by estrogen receptor (ER) status, TT genotype and T allele were associated with a decreased ER-positive breast cancer risk (OR = 0.66, 95 % CI = 0.49-0.90 and OR = 0.85, 95 % CI = 0.75-0.96, respectively). The present meta-analysis results suggest that TGF-β1 -509C/T variants may not contribute to the risk of breast cancer overall. However, T allele may be a potential protective factor for developing ER-positive breast cancer. Well-designed studies with larger sample size were required to verify our findings further.
authors: Henan Center for Disease Control and Prevention, Zhengzhou, 450016, People's Republic of China.
authors: Yadong
authors: Y
authors: Wang
authors: Xinwei
authors: X
authors: Chu
authors: Xiaojing
authors: X
authors: Meng
authors: Fei
authors: F
authors: Zou
mesh_terms: D000483:Alleles; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D053773:Transforming Growth Factor beta1 / Q000235:genetics*
chemical_list: D053773:Transforming Growth Factor beta1
references: Eur J Cancer. 2009 Mar;45(5):837-42
references: 19071013
references: J Cell Mol Med. 2005 Jan-Mar;9(1):208-21
references: 15784178
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):57-69
references: 21068203
references: Cancer Res. 2003 May 15;63(10):2610-5
references: 12750287
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Breast Cancer Res Treat. 2010 Nov;124(1):243-9
references: 20232138
references: J Biol Chem. 1986 Mar 25;261(9):4337-45
references: 3456347
references: Tumour Biol. 2013 Feb;34(1):99-105
references: 23001908
references: Cancer Epidemiol. 2011 Dec;35(6):560-3
references: 21470928
references: Hum Mol Genet. 1999 Jan;8(1):93-7
references: 9887336
references: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1567-70
references: 15941974
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Breast Cancer Res Treat. 2011 Apr;126(3):717-27
references: 20872241
references: Biometrics. 1994 Dec;50(4):1088-101
references: 7786990
references: J Natl Cancer Inst. 2011 Aug 17;103(16):1252-63
references: 21791674
references: Exp Mol Med. 2003 Jun 30;35(3):196-202
references: 12858019
references: Breast Cancer Res Treat. 2010 Apr;120(3):727-36
references: 19672706
references: Int J Radiat Biol. 2003 Feb;79(2):137-43
references: 12569017
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Med Oncol. 2011 Jun;28(2):424-8
references: 20349216
references: Am J Respir Crit Care Med. 2004 Jan 15;169(2):214-9
references: 14597484
references: Methods Mol Biol. 2011;677:303-38
references: 20941619
references: Cell. 2008 Jul 25;134(2):215-30
references: 18662538
references: Breast Cancer Res Treat. 2010 Jan;119(1):201-11
references: 19360465
references: Clin Chim Acta. 2007 May 1;380(1-2):165-9
references: 17368597
references: J Mol Med (Berl). 2006 Jan;84(1):16-28
references: 16283147
references: Eur J Immunogenet. 2004 Feb;31(1):37-42
references: 15009180
references: Hum Immunol. 2008 Jun;69(6):360-7
references: 18571008
references: Breast Cancer Res Treat. 2011 Jun;127(2):309-24
references: 21445572
references: Cancer Genet Cytogenet. 2009 Apr 1;190(1):21-5
references: 19264229
references: Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1112-9
references: 21527583
references: BMC Cancer. 2007 Sep 11;7:175
references: 17848193
references: Breast Cancer Res Treat. 2010 Jul;122(1):273-9
references: 20309626
references: Breast Cancer Res Treat. 2010 Nov;124(2):481-5
references: 20361250
references: Cancer Res. 2004 Feb 1;64(3):836-9
references: 14871809
references: Breast Cancer Res Treat. 2009 Sep;117(1):151-9
references: 19005751
references: Int J Cancer. 2004 Oct 20;112(1):94-9
references: 15305380
references: Int J Cancer. 2007 Mar 15;120(6):1330-5
references: 17187359